                               SEQUENCE LISTING

<110> MODERNA THERAPEUTICS, INC.
 
<120> CHIMERIC POLYNUCLEOTIDES

<130> 2030.1057PCT/M057.20

<140> PCT/US14/xxxxx
<141> 2014-09-03

<150> 61/877,582
<151> 2013-09-13

<150> 61/873,034
<151> 2013-09-03

<160> 11     

<170> PatentIn version 3.5

<210> 1
<211> 22
<212> PRT
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 2A peptide"

<400> 1
Gly Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys Gln Ala Gly Asp Val 
1               5                   10                  15      


Glu Glu Asn Pro Gly Pro 
            20          


<210> 2
<211> 66
<212> DNA
<213> Unknown

<220>
<221> source
<223> /note="Description of Unknown: 2A DNA sequence"

<400> 2
ggaagcggag ctactaactt cagcctgctg aagcaggctg gagacgtgga ggagaaccct       60

ggacct                                                                  66


<210> 3
<211> 18
<212> DNA
<213> Cyanophage Syn5

<400> 3
attgggcacc cgtaaggg                                                     18


<210> 4
<211> 80
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"

<400> 4
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa       60

aaaaaaaaaa aaaaaaaaaa                                                   80


<210> 5
<211> 160
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"

<400> 5
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa       60

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      120

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa                            160


<210> 6
<211> 250
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"


<220> 
<221> misc_feature
<222> (1)..(250)
<223> /note="This sequence may encompass 100-250 bases"

<400> 6
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa       60

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      120

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      180

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      240

aaaaaaaaaa                                                             250


<210> 7
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      oligonucleotide"


<220> 
<221> misc_feature
<222> (1)..(30)
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 7
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa                                        30


<210> 8
<211> 120
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"

<400> 8
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa       60

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      120


<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220> 
<221> MOD_RES
<222> (1)..(1)
<223> N,N-dimethyl-L-valyl

<220> 
<221> MOD_RES
<222> (2)..(2)
<223> L-valyl

<220> 
<221> MOD_RES
<222> (3)..(3)
<223> N-methyl-L-valyl

<220> 
<221> MOD_RES
<222> (4)..(4)
<223> L-prolyl

<220> 
<221> MOD_RES
<222> (5)..(5)
<223> L-proline-t-butylamide

<400> 9
Val Val Val Pro Pro 
1               5   


<210> 10
<211> 120
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"

<400> 10
tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt       60

tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt      120


<210> 11
<211> 200
<212> DNA
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polynucleotide"


<220> 
<221> misc_feature
<222> (1)..(200)
<223> /note="This sequence may encompass 40-200 bases"

<220> 
<221> misc_feature
<222> (1)..(200)
<223> /note="See specification as filed for detailed description of
      substitutions and preferred embodiments"

<400> 11
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa       60

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      120

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa      180

aaaaaaaaaa aaaaaaaaaa                                                  200


